tbuckley/cabot-search huggingface dataset:
MNGO-12. CLONAL SELECTION TOWARD TERT PROMOTER MUTATIONS IN PROGRESSIVE RECURRENT MENINGIOMAS
Authors: Tareq Juratli, Matthias Kirsch, Christian Thiede, Dietmar Krex, Mechthild Krause, Priscilla Brastianos, Daniel Cahill, Gabriele Schackert
Journal: Neuro-Oncology (2016)

Tumor recurrence after therapy is not infrequent in meningioma, and recurrent meningiomas often undergo a grade-progression to become atypical or malignant upon recurrence. To date, few are known about the clonal selection toward specific mutations in progressive meningiomas. Here, we determined the TERT promoter mutations in a large series of recurrent progressive meningiomas. We screened a cohort of 57 recurrent progressive meningiomas of 24 patients for TERT promoter mutations. We further sequenced the TERT promoter in a second cohort consisting of 13 patients with radiation-induced meningiomas. The TERT promoter was amplified using Sanger sequencing performed using ABI Prism 3730 DNA Analyzer. Mutations at the residues at −124 (1295228) and −146 (1295250) bp from the ATG start site in the TERT promoter were scored. Somatic TERT mutations were detected in seven samples from four patients (16.6%) with recurrent meningiomas. Three of four TERT mutations were detected in secondary progressed Grade II to Grade III meningiomas. Intriguingly, two different patients with initially TERT wild-type Grade II meningiomas, who underwent standard therapy with surgery and radiation, then developed a recurrent meningioma with de novo TERT mutation. Conversely, in the cohort of radiation-induced meningiomas, the TERT mutation was detected only in one Grade I meningioma (7.7%). Patients with TERT mutations exhibited a significantly shorter overall survival than patients harboring TERT wild-type meningiomas (3.9 vs 10.9 years, p= 0.008). We have identified the emergence of TERT promoter mutation in recurrent progressive meningiomas, indicating the presence of ongoing and potentially therapy-related clonal selection impacting the natural history of these tumors. Patients with TERT-mutant meningiomas exhibited significantly shorter overall survival than their TERT wild-type counterparts.
Prognostic Utility of Extranodal Disease Involvement in Diffuse Large B-Cell Lymphoma in Patients Treated with R-CHOP.
Authors: David Hui, Jane Donaldson, Paul Hoskins, Richard Klasa, Kerry J. Savage, Tamara Shenkier, Randy D. Gascoyne, Joseph M. Connors, Laurie Sehn
Journal: Blood (2007)
Investigations on Agonal Acidosis.
Journal: Annals of Internal Medicine (1949)

This monograph on the chemical changes in the blood during the agonal state was completed shortly before death prematurely terminated the promising career of the author. It contains the most detailed studies with which the reviewer is acquainted on the chemical composition of the blood during the transition from life to death. Following introductory sections on previous work on agonal acidosis, the clinical aspects of the preterminal state and the concept of acidosis, there is a description of the material and analytic methods used. The results are presented in great detail, with tabular summaries. Twenty-three chemical and physiochemical measurements were carried out on almost all the 38 subjects studied. Unfortunately, sodium and potassium determinations were not done. There is a short section on therapy. Hansen found a fall in blood<i>p</i>H usual in the agonal state. In 18 of the cases values of less than 7.10 were found. The
Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts &lt;100,000/µl
Authors: John Mascarenhas, Ronald Hoffman, Moshe Talpaz, Aaron T. Gerds, Brady Stein, Vikas Gupta, Anita Szoke, Mark Drummond, Alexander Pristupa, Tanya Granston, Robert Daly, James P. Dean, Suliman Al-Fayoumi, Jennifer A. Callahan, Jack W. Singer, Jason Gotlib, Catriona Jamieson, Claire Harrison, Ruben Mesa, Srdan Verstovsek
Journal: Blood (2016)
SRSF2 Mutations Impair Hematopoietic Differentiation By Altering Exonic Splicing Enhancer Preference
Authors: Eunhee Kim, Janine O. Ilagan, Stanley Lee, Aravind Ramakrishnan, Young Rock Chung, Jean-Baptiste Micol, Michele E. Murphy, Min-Kyung Kim, Ahmad S. Zebari, Jacob Feala, Silvia Buonamici, Peter G Smith, H. Joachim Deeg, Camille Lobry, Iannis Aifantis, Robert K. Bradley, Omar Abdel-Wahab
Journal: Blood (2014)
Clinical prognostic factors and genomic analysis of ovary metastases (mets) from colorectal cancer (CRC).
Authors: Karuna Ganesh, Ronak Shah, Efsevia Vakiani, Nancy E. Kemeny, Anne Lincoln, Christina Tran, Anna M. Varghese, Rona D. Yaeger, Andrea Cercek, Neil Howard Segal, Diane Lauren Reidy, Andrew S. Epstein, Martin R. Weiser, Julio Garcia-Aguilar, Michael F. Berger, Leonard Saltz, Zsofia Kinga Stadler
Journal: Journal of Clinical Oncology (2016)

564 Background: Ovary mets constitute 5-10% of CRC mets, are associated with poor prognosis, cause morbidity due to disproportionately rapid growth compared with other mets and are less responsive to chemotherapy. The optimal management of ovary mets and the molecular basis of their unique growth pattern is unknown. Methods: 505 MSKCC patients with CRC (ICD-9 153, 154) and ovary mets (ICD-9 198.6) were identified. Patients without available pathology, with appendix cancer or only serosal ovary mets were excluded. Regression models were used to identify predictors of progression-free survival (PFS) and overall survival (OS) after surgery. Targeted exome sequencing of 341 cancer-associated genes was performed on 34 CRC ovary mets, including 20 matched pairs or trios of primary tumors, ovary mets and other mets from the same patient. Results: 184 patients with surgically resected CRC ovary mets were evaluated (median age 50 (17-86); OS 40 months (0.8-218) from CRC diagnosis, 23 months (0.2-199) from oophorectomy). 93/116 (80.2%) evaluable patients had concurrent growth of ovary mets on chemotherapy but shrinkage of other mets. In multivariate analysis, optimal surgical debulking was associated with improved PFS (HR = 0.11 (0.04-0.36)) and OS (HR = 0.42 (0.28-0.63)). Discordant ovary therapy response was associated with early progression (HR = 20.8 (1.59-274), and post-oophorectomy chemotherapy with reduced mortality (HR = 0.53 (0.33-0.84)). Ovary mets had increased KRAS (61.7% vs. 45.2%, p= 0.05) and SMAD4 (29.4% vs. 15.5%, p= 0.04) mutations compared to a 453 CRC cohort without ovary mets. In matched trios, mutations were largely concordant across tumor sites and no recurrent ovary met-specific mutations were found. However, 3/14 cases had identical mutations in the ovary mets and primary tumors, but additional private mutations in other mets. Conclusions: CRC ovary mets have frequent KRAS and SMAD4 mutations. Matched trios show clonal similarities between primary tumors and ovary mets, and divergence from other mets. Complete surgical resection of ovary mets is associated with substantially improved PFS and OS, similar to outcomes for localized CRC.
Dasatinib in the Treatment of CML Patients Aged &amp;gt; 60 Years Resistant/Intolerant to Imatinib
Authors: Roberto Latagliata, Massimo Breccia, Fabio Stagno, Silvia De Matteis, Mario Annunziata, Ida Carmosino, Laura Cannella, Laura Napoleone, Federico Vozella, Simona Sica, Francesco Di Raimondo, Felicetto Ferrara, Giuliana Alimena
Journal: Blood (2008)
Insufficient Inhibition by Aspirin of Platelet TXA2 Synthesis and Platelet Recruitment Is Associated with Myonecrosis in Patients with ST-Segment Elevation Myocardial Infarction.
Authors: Maria-Teresa Santos, Maria P. Fuset, Antonio Moscardo, Miguel Ruano, Francisca Perez, Silvia Breña, Marta Piñon, Juana Valles
Journal: Blood (2006)
Metabolic Consequences of Restorative Surgery After Gastric Bypass
Authors: Ali Aminian, Stacy A. Brethauer, Neha Parekh, Kareem M. Abu-Elmagd, Philip R. Schauer
Journal: Diabetes Care (2017)

Roux-en-Y gastric bypass (RYGB) improves the metabolic profile of patients with type 2 diabetes mellitus (T2DM). Surgical weight loss can improve insulin sensitivity and β-cell function. Furthermore, there is a growing body of evidence explaining improvement of T2DM after bariatric surgery by weight-independent neurohormonal mechanisms, including changes in gut hormones, bile acids, and gut microbiota. Changes to gastrointestinal anatomy (for example, exclusion of the duodenum in RYGB) can directly influence glucose homeostasis, independent of weight loss (1–3).

Bariatric and metabolic surgery is not without some risk, though, and reoperation is sometimes necessary to manage long-term complications. Metabolic consequences of reoperative bariatric procedures have not been well characterized (4,5). The aim of this report is to present examples of how reoperative surgery can impact the metabolic effects of these operations.

The first patient was a 47-year-old woman with a BMI of 38 kg/m2. She had a history of T2DM …
Isolated Brain Parenchyma Relapse of Non-Hodgkin’s Lymphoma (NHL): A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG).
Authors: Nancy D. Doolittle, Lauren Abrey, Tamara Shenkier, Tali Siegal, Jacoline Bromberg, Edward Neuwelt, Carole Soussain, Patrick Johnston, Gerald Illerhaus, David Schiff, Tracy Batchelor, Silvia Montoto, Emanuele Zucca, Dale Kraemer
Journal: Blood (2006)
Genetic Loss of NFAT2 Leads to CLL Transformation
Authors: Melanie Märklin, Jonas Heitmann, Felicia Truckenmüller, Lothar Kanz, Sebastian Jonas Saur, Manuela Ganser, Bugl Stefanie, Hans-Georg Kopp, Michael Haap, Anjana Rao, Stefan Wirths, Martin R Mueller
Journal: Blood (2015)
ACTR-31. PATTERNS OF COMPLIANCE IN THE USE OF TUMOR TREATING FIELDS (OPTUNE) FOR BRAIN TUMORS
Authors: Manjari Pandey, Lindsey Lands, Brandon Baughman, Madison Michael, Jeffrey Sorenson, Alva Weir, Matthew Ballo
Journal: Neuro-Oncology (2016)

Tumor Treating Fields (TTF) are low-intensity, intermediate frequency, alternating electric fields delivered via a portable medical device (Optune) that is FDA approved for use in glioblastoma. It is recommended to be used for at least 18 hours a day, adherence to therapy is related to survival outcomes. The World Health Organization describes 5 dimensions of compliance: social, economic, medical condition, therapy-related and patient behaviors. We studied these variables in our patient population. We identified all patients that were prescribed Optune TTFs at the West Cancer Center on/after November 2015. We conducted a retrospective chart review till June 2016 and will continue to collect data on patient characteristics, tumor and treatment. Treatment adherence data is collected by the Optune device that records average daily use (hours/day), information is reviewed monthly. From November 2015 - June 2016, 33 prescriptions for Optune were written, 23 patients were due to start therapy but 7 did not start due to tumor progression (3 pts), patient refusal (1 pt), other (3 pts; 1 HSV meningitis, 2 social/financial). Among TTF users, average compliance was 69.73%, range 7.4–94.93%. Seven patients had compliance <75% (no data for 3 pts). Patient reported reasons for not using Optune were intolerance of side effects (4 pts), lack of caregiver support (2 pts), interference with lifestyle (2 pts) and other (3pts). Some patients cited more than one reason for non-adherence. Further data is being collected and will be reported at SNO 2016 meeting. Experience with the use of TTFs is limited, the West Cancer Center is one of the highest volume centers using TTFs; we share our experience with the use of this device. Adherence to TTF therapy is highly variable; we report the compliance patterns in our patients and suggest factors that can be optimized.
Charging overseas patients upfront could cause “chaos,” BMA warns
Authors: Jacqui Wise
Journal: BMJ (2017)

Hospitals in England will have a legal duty to charge patients who are not resident in the UK in advance of non-urgent planned treatment from 1 April, but the BMA has warned that the new regulations could cause “chaos and confusion” and would be a challenge to implement from scratch within such a tight timescale.

Under the new regulations, hospitals will have to check that all patients are eligible for free NHS treatment—for example, by asking them to produce a passport or birth certificate as well as evidence that they are a UK resident, such as a utility bill or bank statement. Hospitals or NHS bodies will then be expected to indicate patients who are chargeable so that the NHS can more easily recoup costs from visitors from overseas.

Hospitals are already supposed to charge patients who live outside the European Economic Area for non-urgent treatment, including elective procedures such as hip operations, but this can be done afterwards by invoice …
The search for the hypersensitivity in chronic cough
Authors: Surinder S. Birring
Journal: European Respiratory Journal (2017)

Chronic cough is a common disorder that affects an estimated 10% of the general population [1]. Adverse symptoms such as urinary incontinence, chest pains, headaches and syncope are frequently associated with cough and lead to poor health-related quality of life [2, 3]. Chronic cough has long been viewed as a symptom of other chronic disorders, hence the current approach to assessing and treating patients focuses on identifying an underlying condition, such as asthma and gastro-oesophageal reflux disease [4]. A significant number of cases of chronic cough, as many as 50%, remain unexplained following detailed assessment. They are often referred to as idiopathic, unexplained or refractory chronic cough [5, 6]. Recently, there has been consensus that chronic cough is a disorder of dysregulated sensory nerves and the associated central processing [7]. In this model, an important symptom reported by patients is an exaggerated sensation of the urge to cough, reflecting a disorder of the primary ascending neurons that innervate the airways and lungs [8]. ATP activation of P2X3 receptors: an important mechanism in cough but does it underlie the hypersensitivity? <http://ow.ly/TNNZ308bu2a>
417P Availability and Utility of Functional Imaging (FI) and Peptide Receptor Radionuclide Therapy (PRRT) in the CommNETS Collaboration (Australia, Canada and New Zealand)
Authors: B.A. Chan, H-W. Sim, A. Ravikumar, D. Bailey, D. Chan, B. Lawrence, A. McEwan, N. Pavlakis, E. Segelov, S. Singh, P. Roach, D. Wyld
Journal: Annals of Oncology (2016)
A triplet combination with oxaliplatin/capecitabine/irinotecan (XELOXIRI) plus cetuximab (Cmab) as a first-line therapy in wild-type KRAS, metastatic colorectal cancer: a dose escalating study
Authors: Y. Sato, H. Ohnuma, M. Hirakawa, S. Kikuch, M. Takahashi, T. Okamoto, Y. Tsuji, K. Okita, T. Furuhata, I. Takemasa, J. Kato
Journal: Annals of Oncology (2016)
Lung cancer screening knowledge and beliefs among primary care providers and pulmonologists.
Authors: Katie Marsh, Mikael Anne Greenwood-Hickman, Laura Jones, M. Patricia Rivera, J. Michael Bowling, Paul Molina, Susan Maygarden, Katherine Birchard, Dan Reuland, Louise Henderson
Journal: Journal of Clinical Oncology (2016)

191 Background: In response to the National Lung Screening Trial’s findings, numerous professional organizations have published guidelines recommending annual lung cancer (LC) screening with low dose computed tomography (LDCT) for eligible patients. In the wake of these guidelines, we sought to assess LC screening practices and beliefs among providers at a large academic medical center. Methods: In 2015, we surveyed 54 physicians and 9 residents in pulmonology (27% response rate) and 86 physicians and 100 residents in family/internal medicine (39% response rate). The 23 question Qualtrics survey focused on beliefs and knowledge about LC screening recommendations, guidelines, and practices. Results: Survey respondents in both groups were mostly White non-Hispanic clinicians with a mean age of 40 (range 28-67). Pulmonology respondents were mostly male (69%) and family/internal medicine respondents were mostly female (53%). The pulmonology group was more likely than family/internal medicine to believe that LC screening is beneficial for patients (p &lt; 0.0001) and cost effective (p = 0.02). Over 76% of the pulmonology group reported ordering a LDCT for an asymptomatic patient in the past 12 months compared to 41% in the family/internal medicine group (p = 0.012). Additionally, 76% in pulmonology were aware of the American College of Chest Physicians recommendations versus 38% in family/internal medicine (p = 0.02). The majority of both groups agreed that an electronic prompt would increase the likelihood of referring a patient for LC screening. While both groups agreed that a LC screening registry would benefit the quality of patient care (100% pulmonology; 65% family/internal medicine; p = 0.02) and make them more likely to refer patients to a LC screening program (88%; 54%; p = 0.04), a significantly larger majority of the pulmonology group held these beliefs. Conclusions: Pulmonology respondents had more knowledge of guidelines and more favorable opinions of LC screening than family/internal medicine respondents. Our findings suggest future studies should focus on educating providers about recommendations and understanding why the family/internal medicine group is less likely to refer patients for LC screening.
A Patient With Hypertrophic Cardiomyopathy Presenting in Cardiac Arrest
Authors: Jin Ge, Nora Goldschlager
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
BCR/ABL and Other Oncogenic Fusion Tyrosine Kinases (FTKs) Stimulate Single Strand Annealing (SSA), the Rare and Extremely Unfaithful DNA Double-Strand Break Repair Pathway To Facilitate Genomic Instability in Hematologic Malignancies.
Authors: Kimberly Cramer, Emir T. Penserga, Akhil Reddy, Jonathan Wosen, Tomasz Skorski
Journal: Blood (2007)
Erratum: Corrigendum: Zika viral dynamics and shedding in rhesus and cynomolgus macaques
Authors: Christa E Osuna, So-Yon Lim, Claire Deleage, Bryan D Griffin, Derek Stein, Lukas T Schroeder, Robert Omage, Katharine Best, Ma Luo, Peter T Hraber, Hanne Andersen-Elyard, Erwing Fabian Cardozo Ojeda, Scott Huang, Dana L Vanlandingham, Stephen Higgs, Alan S Perelson, Jacob D Estes, David Safronetz, Mark G Lewis, James B Whitney
Journal: Nature Medicine (2017)
Limited Reliability of Ig/TCR Based MRD Monitoring in BCR/ABL-Positive Childhood ALL: Comparison to Quantitative Fusion Transcript Detection.
Authors: Katerina Krejcikova, Katerina Muzikova, Eva Fronkova, Marketa Kalinova, Leona Reznickova, Jan Zuna, Jan Stary, Jan Trka
Journal: Blood (2006)
The final results of a multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201)
Authors: H. Bando, T. Doi, K. Muro, H. Yasui, T. Nishina, K. Yamaguchi, S. Takahashi, H. Hasegawa, S. Nomura, H. Kuno, K. Shitara, A. Sato, A. Ohtsu
Journal: Annals of Oncology (2016)
YOCAS yoga for musculoskeletal symptoms in breast cancer patients receiving aromatase inhibitors: A URCC CCOP randomized, controlled clinical trial.
Authors: Luke Joseph Peppone, Supriya Gupta Mohile, Michelle Christine Janelsins, Lisa Sprod, Jennifer S. Gewandter, Charles E. Heckler, Kavita Dayal Chandwani, Gary R. Morrow, Janet C. Ruzich, Benjamin Esparaz, Karen Michelle Mustian
Journal: Journal of Clinical Oncology (2012)

9028 Background: Up to 50% of breast cancer patients on aromatase inhibitor therapy report significant musculoskeletal symptoms such as joint and muscle pain, which decreases treatment adherence. We conducted a secondary data analysis of a multi-site, phase III randomized, controlled, clinical trial examining the efficacy of yoga for improving musculoskeletal symptoms among breast cancer patients currently receiving hormone therapy (aromatase inhibitors [AI] or tamoxifen [TAM]) through the University of Rochester Cancer Center Community Clinical Oncology Program (CCOP). Methods: The original RCT randomized patients with any type of non-metastatic cancer without previous yoga participation into 2 arms: 1) standard care monitoring [controls] or 2) 4-week yoga intervention (2x/wk; 75 min/session) plus standard care. The yoga intervention utilized the UR Yoga for Cancer Survivors (YOCAS) program consisting of breathing exercises, 18 Hatha and Restorative yoga postures, and meditation. Only breast cancer patients currently receiving AI (N=95) or TAM (N=72) were included in this secondary analysis. Changes in musculoskeletal symptoms were assessed using ANCOVA with baseline values as covariates between the yoga and control groups. Results: Compared to TAM users at baseline, AI users reported higher levels of general pain (1-5 score: AI=2.65 vs. TAM=2.17; p=0.01), muscle aches (0-4 score: AI=2.14 vs. TAM=1.65; p=0.01), and total physical discomfort (0-24: AI=8.03 vs. TAM=5.92; p=0.01). Among AI users only, participants in the yoga group demonstrated greater reductions in general pain (CS=change score; Yoga CS= -0.37 vs. Control CS= +0.02; p=0.02), muscle aches (Yoga CS= -0.58 vs. Control CS= -0.15; p=0.03) and total physical discomfort (Yoga CS= -2.07 vs. Control CS= -0.58; p=0.04) from pre- to post-intervention than the control group. Conclusions: The severity of musculoskeletal symptoms was higher for AI users than for TAM users. Among breast cancer patients on AI therapy, the community-based YOCAS intervention significantly reduced general pain, muscle aches, and physical discomfort. Funding: NCI U10CA37420, KL2RR024136-05, K07CA120025.
Which Surgical Approach Is Best for Management of Rectal Cancer?
Authors: Lakhbir Sandhu, George J. Chang
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal